Introduction
T1D, AiDAPT, diabetes
TYPE 1 DIABETES, TYPE 1 DIABETES, TYPE 1 DIABETES, DIABETES
Pregnant women with type 1 diabetes (T1D) are advised to aim for target glucose levels of 3.5–7.8 mmol/L for at least 70% of the day.Closed-loop systems have begun to transform T1D management.Healthcare professionals play pivotal roles in mediating people's expectations, experiences, and use of diabetes technologies.To address this gap in the literature and provide bespoke recommendations for supporting HCL use in pregnancy, we report findings from interviews with healthcare professionals who participated in a UK-based, multicenter, randomized controlled trial—Automated insulin Delivery Amongst Pregnant women with Type 1 diabetes (AiDAPT). The trial, which began in September 2019 and closed out in November 2022, explored the biomedical and psychosocial effects of using HCL (CamAPS FX) compared with CGM in pregnant women (aged 18–45 years) receiving routine clinical care.The Closed-Loop System Used During the TrialCGM, continuous glucose monitor; GMI, Glucose Management Indicator; HbA1c, glycated hemoglobin; HCL, hybrid closed-loop.Healthcare professionals at local sites, working alongside a research educator, trained women to use the system, provided study-related support, and were responsible for participants' routine clinical care. Due to the Covid-19 pandemic, research visits and device training were available virtually via video call or telephone, and most participants' diabetes appointments were also offered virtually, mirroring practices in routine clinical care. For further details regarding the AiDAPT trial and training provided, see Details About the Automated Insulin Delivery Amongst Pregnant Women with Type 1 Diabetes Trial and Training ProvidedAiDAPT, Automated insulin Delivery Amongst Pregnant women with Type 1 diabetes; MDI, multiple daily injections; T1D, type 1 diabetes.Elsewhere, we have described how healthcare professionals favored an inclusive approach to HCL use and rollout due to their perception and understanding that virtually all pregnant women can experience clinical and/or quality-of-life benefits from using a HCL.